BFM
NEUP

Boothbay Fund Management’s Neuphoria Therapeutics NEUP Stock Holding History

Boothbay Fund Management’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$57K Hold
14,000
– – ﹤0.01% 1913
2025
Q4 		$54.3K Buy
+14,000
New +$99.5K ﹤0.01% 1814

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Boothbay Fund Management's NEUP Position: Q1 2026 in Review

Boothbay Fund Management held its Neuphoria Therapeutics (NEUP) position steady in Q1 2026 at 14,000 shares worth $57K. The position accounts for ﹤0.01% of the portfolio, ranked #1913.

Boothbay Fund Management first reported a position in NEUP in Q4 2025 and has held it in 2 quarters since. 19 funds tracked by Wall St. Rank hold NEUP as of Q1 2026.

  • Boothbay Fund Management held 14,000 shares of Neuphoria Therapeutics worth $57K as of Q1 2026.
  • Boothbay Fund Management left its Neuphoria Therapeutics share count unchanged in Q1 2026.
  • Neuphoria Therapeutics made up ﹤0.01% of Boothbay Fund Management's portfolio in Q1 2026, its #1913 holding.
  • Boothbay Fund Management first reported a position in Neuphoria Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 19 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.